NRG Pallas

Name

NRG Pallas

Legal name

Nuclear Research and consultancy Group v.o.f.

Website

https://nrgpallas.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Medical Isotope Production & Nuclear Services

NAICS

Irradiation Apparatus Manufacturing (334517)

SIC

Services-Commercial Physical & Biological Research (8731), Hazardous Waste Management (4955)

akta.pro primary industry

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

akta.pro secondary industries

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA), Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE), Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD)

Keywords

• Medical isotope production
• Nuclear energy services
• Radiation protection training
• Radiopharmaceutical isotopes
• Nuclear reactor operations

Headquarters

HQ city

Arnhem

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Medical Isotope Sales: Production and sale of medical isotopes including Molybdenum-99, Lutetium-177, Terbium-161, Yttrium-90, and Iridium-192 to hospitals, pharmaceutical companies, and healthcare providers worldwide. Daily supply supports over 30,000 cancer patients globally.
2. Nuclear Energy Services: Consulting and services for existing and new nuclear reactors including safety analyses, licensing support, in-service inspections, long-term operation planning, fuel management, and waste management & decommissioning.
3. Education & Training (Academy): Radiation protection and nuclear technology courses for professionals. Offerings include certification programs (SBD-CD, TMS levels), refresher courses, and customized training for organizations.
4. PALLAS Reactor Construction: Construction of the new PALLAS reactor in Petten to replace the High Flux Reactor (HFR), securing long-term medical isotope production capacity.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Core offering

NRG Pallas operates the High Flux Reactor (HFR) in Petten to produce medical isotopes such as Molybdenum-99, Lutetium-177, Terbium-161, Yttrium-90, and Iridium-192 used in cancer diagnosis and treatment. It also provides nuclear energy consulting (safety analyses, licensing, in-service inspections, fuel and waste management) for existing and new reactors, and runs the NRG PALLAS Academy for radiation protection and nuclear technology training. The company is building the new PALLAS reactor to replace the HFR.

Product overview

NRG PALLAS is a nuclear technology company offering a unified portfolio of products and services centered on medical isotopes and nuclear energy. The core offerings include Medical Isotope Solutions (radioisotopes and radiochemicals like Molybdenum-99, Lutetium-177, Terbium-161, Yttrium-90, Iridium-192, and Lead-212), Nuclear Energy Services (supporting both new and existing reactors including SMR development, safety analyses, and radiation protection), and the NRG PALLAS Academy (radiation protection training and certification). The company is also constructing the PALLAS-reactor in Petten to replace the aging High Flux Reactor and secure future medical isotope supply. Research programs focus on Nuclear for Life, Nuclear for Health, and Nuclear for Energy, including proprietary tools like MUSCLE-Foam for molten salt reactor simulation.

Differentiator

Problem solved

Functional benefit

Brands

• PALLAS Programme: The dedicated project organization responsible for the construction of the PALLAS reactor and its supporting infrastructure
• NRG PALLAS Academy
• PALLAS-reactor
• MUSCLE-Foam
• Hoge Flux Reactor (HFR)
• Hot Cells

Products and services

• Medical Isotope Solutions Portfolio of nuclear medicine products including radioisotopes (Mo-99, Lu-177, Tb-161, Y-90, Ir-192) and radiochemicals (Lu-177 n.c.a., Pb-212) for diagnostic imaging and cancer treatment. Supplied to hospitals, cancer treatment centers, and pharmaceutical companies globally, supporting over 30,000 patients daily.
• Nuclear Energy Services Services for safe and reliable operation of reactors and nuclear facilities, including new-build programs, SMR and advanced reactor development support, fuels and materials irradiations, in-service inspections, licensing, safety analyses, long-term operation planning, fuel management, and waste management & decommissioning.
• NRG PALLAS Academy Education and training services offering courses in radiation protection and nuclear technology, including certification programs (SBD-CD, TMS levels) for radiation protection experts and refresher courses. Delivered in-person at Petten or as e-learning through the Academy Portal (PlusPort).
• Medical Radioisotopes Standalone radioisotope products including Molybdenum-99 (for Tc-99m generators), Lutetium-177 (for radioligand therapy), Terbium-161, Yttrium-90, and Iridium-192 used in nuclear medicine for diagnosis and treatment.
• Radiochemicals Nuclear medicine chemicals including Lutetium-177 n.c.a. (non-carrier-added) and Lead-212 supplied to pharmaceutical partners for therapeutic radiopharmaceutical applications.
• Radiation Protection Services Operational radiation protection support, laboratory services, measuring/monitoring/calibrations, and ReGuard solutions for nuclear facilities and radiation-handling organizations.
• MUSCLE-Foam Simulation Software Open-source computer code developed by NRG PALLAS for simulating molten salt reactors, based on OpenFOAM thermohydraulics software with added neutronics models enabling coupled reactor physics and thermal-hydraulics simulations.
• PALLAS Reactor (New-build Project) New nuclear reactor under construction in Petten to replace the High Flux Reactor (HFR), designed to secure global medical isotope production capacity with Hot Cells integrated into the design.

Quantifiable outcome

• 30,000+ patients helped daily with products
• +2 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and major.

• FCC (Construction)coreImplementation/ SI/ Consulting Partner · 2 June 2026Agreement for supply and installation of Hot Cells for the new PALLAS reactor. FCC executes work with contracting company Asturfeito as specialized partner for Hot Cells. Critical milestone for reactor construction in Petten.
• AsturfeitocoreImplementation/ SI/ Consulting Partner · 2 June 2026Specialized partner for Hot Cells supply as part of the FCC construction partnership for the PALLAS reactor. Provides technically complex and crucial Hot Cells components.
• ICHO (Design Representative)majorTechnology or Integration · 2 June 2026Design Representative for the PALLAS reactor project, working with NRG PALLAS as future operator, FCC as construction partner, and Asturfeito as specialist supplier.
• KAIROS POWERcoreStrategic or Co-development Partner · 30 April 2026Material research partnership for advanced Small Modular Reactors (SMRs). Second phase of graphite research underway in the HFR in Petten, testing TRISO fuel and metal components. HFR enables materials testing up to 10x faster than normal, essential for reactor design validation and licensing.
• TAG1 Inc.coreStrategic or Co-development Partner · 22 April 2026Letter of Intent to jointly expand availability of lead-212 (Pb-212) for next-generation cancer therapies in Europe. Combines TAG1's portable Pb-212 generator with NRG PALLAS's high-purity radium-224 production capabilities. Supports the Lead4Life public-private partnership for Pb-212 based radiopharmaceuticals.
• Global Morpho PharmacoreStrategic or Co-development Partner · 7 April 2026Strategic partnership to establish a sustainable and independent supply chain for non-carrier-added lutetium-177 chloride in Petten. Global Morpho Pharma's KaLupso automated radiochemistry platform will be integrated into NRG PALLAS's GMP isotope production facility. Target: first commercial delivery early 2027. Supports over 100,000 patients annually who could benefit from Lu-177 therapies.
• Nexus-NL Consortium (Amentum Clean Energy, Tractebel Engineering, NRG PALLAS)coreStrategic or Co-development Partner · 22 January 2026Consortium selected by Dutch Ministry of Climate and Green Growth to support development of two new nuclear power plants in the Netherlands. NRG PALLAS brings nuclear expertise to the consortium led by Amentum Clean Energy.
• AllseascoreStrategic or Co-development Partner · 17 November 2025SMR technology partnership for high-temperature gas-cooled reactor technology. Allseas impact study projects €130 billion contribution to Dutch economy by 2050, 110 reactors on Dutch land and 700 globally, 35,000-40,000 new jobs.
• TU DelftcoreStrategic or Co-development Partner · 17 November 2025Academic partner in SMR technology development alongside Allseas and NRG PALLAS for high-temperature gas-cooled reactor technology targeting first reactors operational by 2030.
• ThorizoncoreStrategic or Co-development Partner · 17 April 2025MoU signed to build Europe's first commercial molten salt reactor in Netherlands. NRG PALLAS to help realize the Thorizon PIONEER demonstration reactor on the Energy & Health Campus in Petten and jointly operate it. Thorizon spin-off from NRG PALLAS organization.

Scale indicators11 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• GE HealthCare: Global medical imaging and nuclear medicine incumbent offering PET/SPECT tracers, radiopharma production, and imaging hardware. Adjacent to NRG PALLAS as a major downstream consumer of medical isotopes for its diagnostic and therapeutic portfolio.
• Framatome: Major international nuclear reactor services and fuel manufacturer providing engineering, licensing, and operational support to nuclear utilities. Overlaps with NRG PALLAS's nuclear consulting and new-build services across safety analyses, fuel management, and licensing.

Direct peers

• Curium: Global nuclear medicine leader producing Mo-99, Lu-177, and other medical isotopes from reactors in the Netherlands, France, and elsewhere. Direct competitor to NRG PALLAS in supplying pharmaceutical companies and hospitals with reactor-produced isotopes for diagnosis and therapy.
• Studsvik: Swedish nuclear services company providing fuel and materials testing, consulting, and decommissioning services. Comparable to NRG PALLAS in offering specialized nuclear consulting and fuel/materials irradiation expertise to utilities and reactor developers.
• Lantheus Holdings: Radiopharmaceutical company developing and commercializing diagnostic imaging agents and, increasingly, therapeutic radioligands. Comparable to NRG PALLAS as a downstream customer and partner for Mo-99-derived and Lu-177-based products.
• Canadian Nuclear Laboratories: Government-owned nuclear science and technology organization operating research reactors and providing nuclear energy services, isotope production, and decommissioning expertise. Closely mirrors NRG PALLAS's mandate of operating government-aligned nuclear research infrastructure.
• IBA (Ion Beam Applications): Belgian company and one of the largest producers of medical radioisotopes worldwide, leveraging cyclotrons and accelerator-based production. Comparable to NRG PALLAS in serving the radiopharmaceutical supply chain with complementary production technologies.
• National Nuclear Laboratory (UK): UK government-owned nuclear research laboratory providing technical services across the nuclear fuel cycle, reactor operations support, and isotope-related research. Directly comparable as a national nuclear lab providing consulting, R&D, and applied nuclear services.
• BWXT Medical: Subsidiary of BWX Technologies focused on medical isotope production, including Mo-99, and radiopharmaceutical contract manufacturing. Directly comparable to NRG PALLAS in supplying reactor-produced isotopes to the global radiopharma market.

Emerging players

• SHINE Technologies: US-based fusion and medical isotope company developing accelerator-driven production of Mo-99 and Lu-177 as alternatives to reactor-based supply. Comparable to NRG PALLAS as a current/future competitor in the medical isotope market using a fundamentally different production technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/nrgpallas
• LinkedInlinkedin.com/company/nrg_2
• Instagraminstagram.com/nrgpallas
• Xx.com/nrgcom

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NRG Pallas